Education
About Us
Working with TipRanks
Follow Us
Iteos Therapeutics, Inc. (ITOS)
:ITOS
RESEARCH TOOLSreports
ITOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.67 - $18.75
Previous CloseN/A
Volume59.28K
Average Volume (3M)265.84K
Market Cap
$270.99M
Enterprise Value-$42.77M
Total Cash (Recent Filing)$146.65M
Total Debt (Recent Filing)$5.82M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 08, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding38,194,340
10 Day Avg. Volume387,269
30 Day Avg. Volume265,838
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.74
Price to Cash Flow (P/CF)12.30
P/FCF Ratio12.30
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.66
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$25.00Price Target Upside254.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
iTeos Therapeutics News
PremiumCompany Announcements
iTeos Therapeutics Plans 2025 Data Presentation on Therapies
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe upcoming topline update and detailed presentation from iTeos’ GALAXIES-Lung-201 trial could help build confidence, particularly if the bel + dostarlimab combination has a strong showing in preliminary outcomes.
Financial HealthThe company holds cash and cash equivalents of approximately $655 million, deemed sufficient to fund its operations and upcoming studies.
Bears Say
Financial PerformanceThe company reported no revenue and a net loss, with projections indicating continued losses in the future.
Program DevelopmentBased on the data, management believes that inupadenant does not demonstrate sufficient clinical activity to warrant further investment and is electing not to pursue further development of the program.
Safety ConcernsInterim data from a study showed a high occurrence of treatment-related adverse events, leading to amendments in the study protocol to address safety concerns.
---
Ownership Overview
24.52% Insiders
11.99% Mutual Funds
<0.01% Other Institutional Investors
53.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITOS FAQ
What was Iteos Therapeutics, Inc.’s price range in the past 12 months?
Iteos Therapeutics, Inc. lowest stock price was $6.67 and its highest was $18.75 in the past 12 months.
What is Iteos Therapeutics, Inc.’s market cap?
Iteos Therapeutics, Inc.’s market cap is $270.99M.
When is Iteos Therapeutics, Inc.’s upcoming earnings report date?
Iteos Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 60 days.
How were Iteos Therapeutics, Inc.’s earnings last quarter?
Iteos Therapeutics, Inc. released its earnings results on Mar 05, 2025. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.032 by $0.022.
Is Iteos Therapeutics, Inc. overvalued?
According to Wall Street analysts Iteos Therapeutics, Inc.’s price is currently Undervalued.
Does Iteos Therapeutics, Inc. pay dividends?
Iteos Therapeutics, Inc. does not currently pay dividends.
What is Iteos Therapeutics, Inc.’s EPS estimate?
Iteos Therapeutics, Inc.’s EPS estimate is -1.
How many shares outstanding does Iteos Therapeutics, Inc. have?
Iteos Therapeutics, Inc. has 38,194,340 shares outstanding.
What happened to Iteos Therapeutics, Inc.’s price movement after its last earnings report?
Iteos Therapeutics, Inc. reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.032. Following the earnings report the stock price went up 5.985%.
Which hedge fund is a major shareholder of Iteos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ITOS
---
iTeos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (254.61% Upside)
$25.00 (254.61% Upside)
Blogger Sentiment
Bullish
ITOS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $38.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.11%
12-Months-Change
Fundamentals
Return on Equity
-23.06%
Trailing 12-Months
Asset Growth
2.90%
Trailing 12-Months
Company Description
Iteos Therapeutics, Inc.
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
---
ITOS Stock 12 Month Forecast
Average Price Target
$25.00
▲(254.61% Upside)
Technical Analysis
Best Analysts Covering ITOS
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-18.94%
assigned a buy rating 6 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -18.94% per trade.
---